Clinical data
Other names1-Cyclopropylmethylclonazepam, Kloniprazepam, 2-Chloro-7'-nitroprazepam
Drug classBenzodiazepines
Legal status
Legal status
  • 5-(2-Chlorophenyl)-1-(cyclopropylmethyl)-7-nitro-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass369.81 g·mol−1
3D model (JSmol)
  • O=C1N(CC2CC2)C3=CC=C([N+]([O-])=O)C=C3C(C4=CC=CC=C4Cl)=NC1
  • InChI=1S/C19H16ClN3O3/c20-16-4-2-1-3-14(16)19-15-9-13(23(25)26)7-8-17(15)22(11-12-5-6-12)18(24)10-21-19/h1-4,7-9,12H,5-6,10-11H2
Metabolic pathway of cloniprazepam

Cloniprazepam is a benzodiazepine derivative and a prodrug of clonazepam, 7-aminoclonazepam, and other metabolites.[1][2]

Some of the minor metabolites include 3-hydroxyclonazepam and 6-hydroxyclonazepam, 3-hydroxycloniprazepam and ketocloniprazepam with ketone group formed where 3-hydroxy group was.[1]

It is a designer drug and an NPS (short for "new psychoactive substance").[1] At the end of 2017, cloniprazepam was an uncontrolled substance in most of the countries.

See also


  1. ^ a b c Moosmann B, Bisel P, Franz F, Huppertz LM, Auwärter V (November 2016). "Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam". Journal of Mass Spectrometry. 51 (11): 1080–1089. Bibcode:2016JMSp...51.1080M. doi:10.1002/jms.3840. PMID 27535017.
  2. ^ Mortelé O, Vervliet P, Gys C, Degreef M, Cuykx M, Maudens K, et al. (May 2018). "In vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry". Journal of Pharmaceutical and Biomedical Analysis. 153: 158–167. doi:10.1016/j.jpba.2018.02.032. hdl:10067/1496330151162165141. PMID 29494888. S2CID 3946404.